-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Group’s Lurasidone Hydrochloride Tablets Approved
Category:
发布时间：2023-02-21
【概要描述】
On February 20, Shijiazhuang Sihua Pharmaceutical Group achieved another milestone in scientific research and innovation: its application for lurasidone hydrochloride tablets (40 mg) was granted a Drug Registration Certificate by the National Medical Products Administration, which also recognizes the product as having passed the evaluation of quality and therapeutic equivalence for generic drugs. To date, the Group has had 38 drug varieties across 50 specifications approved through this equivalence assessment.
On February 20, Shijiazhuang Sihua Pharmaceutical Group achieved another milestone in scientific research and innovation: its application for lurasidone hydrochloride tablets (40 mg) was granted a drug registration certificate by the National Medical Products Administration, which also recognizes the product as having passed the evaluation of quality and therapeutic equivalence for generic drugs. To date, the Group has had 38 drug varieties across 50 specifications approved through this evaluation.
According to reports, lurasidone hydrochloride is an antipsychotic medication indicated for the treatment of schizophrenia.
Previously, the raw material of lurasidone hydrochloride submitted by the Group’s Hebei Guolong Pharmaceutical Co., Ltd. was approved by the National Medical Products Administration in July 2021 and registered as a raw material used in marketed dosage forms. The recent approval of lurasidone hydrochloride tablets will play a positive role in advancing the Group’s “API + formulation” strategy.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091